Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.

ABSTRACT: Direct-acting antivirals (DAAs) have dramatically improved the management of chronic hepatitis C (CHC). In this study, we investigated the effects of hepatitis C virus clearance on markers of systemic inflammation measured in plasma samples from CHC patients before, during and after DAA therapy. We identified a plasma soluble protein profile associated with CHC. Successful DAA therapy rapidly normalised the plasma inflammatory milieu, with the notable exception of soluble (s)CD163, a marker of macrophage activation, which remained elevated after viral clearance and segregated patients with high and low levels of cirrhosis. Patients who received DAA in combination with Ribavirin maintained elevated levels of CXCL10, consistent with an immune-stimulatory role of Ribavirin. As anticipated, DA

SUBMITTER: Gorin JB 

PROVIDER: S-EPMC7005788 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature